drugset / Trial / NCT00196755

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

NCT00196755

Phase 3 Completed 138 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.

Timeline

Start
2004-12
Primary completion
2006-03
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium carbonate Other / unclassified
Subject Sevelamer Other / unclassified